Zevorcabtagene autoleucel injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: CARsgen Life Sciences (Shanghai) Co., Ltd.
Medicine type: Biologic
Therapeutic area: Oncology
Indications recorded in the public source: For adults with relapsed or refractory multiple myeloma that has progressed after at least three lines of treatment, including at least one proteasome inhibitor and an immunomodulatory agent.
Indication source and scope: Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
Prescribing-information limitations: Indications checked against an official public submission. The full original prescribing information is still unavailable.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Commercial insurance list only; not included in basic insurance
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: The commercial-insurance formulary is not funded by basic medical insurance; coverage depends on the individual commercial insurance contract.
Insurance verification notes: Exact match in the commercial insurance list; the basic insurance notice excludes payment.

Sources

Open the interactive record, public price references and discussions